CALCULATED LOW-DENSITY-LIPOPROTEIN CHOLESTEROL SHOULD NOT BE USED FORMANAGEMENT OF LIPOPROTEIN ABNORMALITIES IN PATIENTS WITH DIABETES-MELLITUS

Citation
J. Rubiesprat et al., CALCULATED LOW-DENSITY-LIPOPROTEIN CHOLESTEROL SHOULD NOT BE USED FORMANAGEMENT OF LIPOPROTEIN ABNORMALITIES IN PATIENTS WITH DIABETES-MELLITUS, Diabetes care, 16(8), 1993, pp. 1081-1086
Citations number
41
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Endocrynology & Metabolism","Medicine, General & Internal
Journal title
ISSN journal
0149-5992
Volume
16
Issue
8
Year of publication
1993
Pages
1081 - 1086
Database
ISI
SICI code
0149-5992(1993)16:8<1081:CLCSNB>2.0.ZU;2-O
Abstract
OBJECTIVE - To assess the validity of calculated low- density lipoprot ein cholesterol by the Friedewald formula for management of lipoprotei n abnormalities in patients with diabetes mellitus. RESEARCH DESIGN AN D METHODS - Calculated LDL cholesterol by the Friedewald formula was c ompared with measured LDL cholesterol after separation by ultracentrif ugation in 61 patients with type I diabetes, 50 patients with type II diabetes, and 116 healthy control subjects. RESULTS - Calculated LDL c holesterol coincided with measured LDL cholesterol, with < 1 0% error, in 54 (49%) patients with diabetes mellitus, and 85 ( 73%) control su bjects. Calculated LDL cholesterol was overestimated, with an error of greater-than-or-equal-to 10% of measured LDL cholesterol in 39% of pa tients and 26% of control subjects, and underestimated in 13 and 1%, r espectively. Despite a good correlation between calculated and measure d LDL cholesterol, the intraclass correlation coefficients demonstrate d a poor concordance between calculated and measured LDL cholesterol, both in patients and control subjects. When comparing the mean differe nces of calculated and measured LDL cholesterol for diabetic subjects versus control subjects, significantly greater differences in type II (but not type I) diabetic subjects were seen. CONCLUSIONS - Calculatio n of LDL cholesterol by the Friedewald formula may be inaccurate for a ssessment of cardiovascular risk in patients with type II diabetes and may not be appropriate for management of lipoprotein abnormalities in those diabetic patients.